Navigation Links
Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
Date:8/5/2008

Nexavar Net Sales increase 107% over Second Quarter 2007

EMERYVILLE, Calif., Aug. 5 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today reported its financial results for the three and six months ended June 30, 2008. Onyx reported net income of $4.5 million, or $0.08 per diluted share, for the second quarter of 2008 compared to a net loss of $10.8 million, or $0.22 per diluted share, in the same period in 2007. Excluding employee stock-based compensation expense, non-GAAP net income for the second quarter of 2008 was $8.7 million, or $0.15 per diluted share, compared to a non-GAAP net loss of $7.2 million, or $0.15 per diluted share, in the same period in 2007. A description of the non-GAAP calculations is provided below in the accompanying Reconciliation of GAAP to Non-GAAP Net Income.

Global Nexavar net sales as reported by Bayer HealthCare Pharmaceuticals, Inc., or Bayer, were $168.5 million for the quarter ended June 30, 2008, a 107% increase over the $81.3 million reported in the same period in 2007. Onyx with its collaborator, Bayer, is marketing and developing Nexavar(R) (sorafenib) tablets, an anticancer therapy currently approved for the treatment of liver cancer and advanced kidney cancer in the U.S., European Union, and other territories internationally.

"We are pleased with the strong revenues and continued momentum for Nexavar globally with net sales reaching $168.5 million in the second quarter, indicating expanding global demand for the brand. Based on a series of rolling launches worldwide, we expect to see additional growth opportunities for Nexavar, particularly for the treatment of liver cancer," said Tony Coles, M.D., president and chief executive officer of Onyx. "With
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Terascala, the industry leader in ... a former vice president of product management for Flexera ... of marketing. Terascala’s software when combined with leading compute ... highest performance and most reliable solutions for processing big ... channel expansion and broaden its product portfolio. His leadership ...
(Date:7/10/2014)... 2014 Senior supply chain management executives ... addressed the challenges of “Reducing Cost, Lead Time, & ... strategic sourcing. Describing the partnership of the Bio Supply ... Management Institute ( SCMI) of the University of ... at the Kroc Institute of Peace and Justice in ...
(Date:7/10/2014)... , July 10, 2014 Research and ... of the "International Photonic Integrated Circuit (Monolithic ... to 2019" report to their offering. ... The concept of photonic integration traces its roots ... The promise of photonic integration went unexplored and ...
(Date:7/10/2014)... the journal PNAS (Proceedings of the National Academy ... and sleep deprivation have a significant effect on our ... the best time of day to test for diseases ... medicines effectively. , Researchers from the University of Surrey ... links between sleep deprivation, body clock disruption and metabolism, ...
Breaking Biology Technology:Terascala Expands Executive Team 2Terascala Expands Executive Team 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Time of day crucial to accurately test for diseases, new research finds 2
... Accounting Oversight Board (PCAOB) will place a greater ... numerous studies, including our own, that show IT change ... the investment to fix your change management process because ... compliance program. , ,PCAOB Release number 2006-007, a ...
... Wis. - Perscitus Biosciences, a Madison biotechnology company, ... Department of Commerce . , ,Perscitus Biosciences was ... based on reactive oxygen biochemistry. James Thomas, CEO and ... be used to purchase equipment and hire researchers to ...
... what many deemed a historic meeting between Steve Jobs ... Wall Street Journal's schmooze-fest titled D: All Things Digital. While ... Age were cordial and humble (a word I have not often ... of competition and cooperation in the most mutually complimentary terms (you ...
Cached Biology Technology:Why IT change management is more important than ever 2Why IT change management is more important than ever 3Why IT change management is more important than ever 4What if Jobs and Gates had teamed up? 2What if Jobs and Gates had teamed up? 3What if Jobs and Gates had teamed up? 4
(Date:7/10/2014)... in New Mexico, nearly every public golf course is ... potable water supplies. Across the U.S. Southwest as a ... treated effluent. Reusing the effluent increases the sustainability of ... alike fertilize their lawns during the growing season. The ... State University turfgrass expert has a new vision for ...
(Date:7/10/2014)... Mass. , June 30, 2014  Aware, Inc. ... biometrics software and services, previously announced on June 26, ... special cash dividend of $1.75 per share, or approximately ... date of July 10, 2014 and a payment date ... by NASDAQ that it had set an ex-dividend date ...
(Date:7/10/2014)... N.Y. , July 2, 2014 It ... (ABD) to announce the appointment of the world-renowned Thoracic ... Board of Directors. Dr. Ginsburg, with over ... facilities: NY Presbyterian Hospital and Good Samaritan Regional Medical ... Pacemaker since the late 1980,s and is considered an ...
Breaking Biology News(10 mins):'Tailored' water -- the latest in lawn care 2NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2
... There are potentially effective treatments for acute myeloid leukemia ... of cases. In a paper published today in Leukemia ... has pinpointed a protein that could play a key, previously ... new information in the quest to treat and cure childhood ...
... Complex heritable traits are not only determined by changes ... Groningen Bioinformatics Centre, together with their French colleagues, have ... flowering time and architecture in plants. Furthermore, these marks ... manner. Their results were published in Science ...
... will be equipped with a new, online information system ... disorders, thanks to 3.5m European Union funding for EMBalance. ... involve researchers from ten different partners, spread across seven ... dizziness etc.) affect more than a third of the ...
Cached Biology News:New target isolated for leukemia drug development 2Revolutionary new view on heritability in plants 2Revolutionary new view on heritability in plants 3€3.5m to improve diagnosis of balance disorders 2
... Disruption of the mitochondrial transmembrane potential ... events that occur following induction of ... Kit utilizes a lipophilic cation, termed ... marker. MitoLight is a mitochondrial dye ...
... Detection Kit contains a green fluorescent-labeled inhibitor, ... of valylalanylaspartic acid (VAD) fluoromethyl ketone (FMK), ... When added to a population of cells, ... and covalently binds to a reactive cysteine ...
... ChipWriter Pro system, 220-240 V, uses floating ... oligonucleotides, carbohydrates, lipids, and other biomolecules onto ... This system can generate high-density arrays with ... or greater than 57,000 spots per membrane ...
... arrays have been developed for affinity ... A variety of ProteinChip chemical surfaces ... to their unique biochemical properties. Each ... side-by-side sample comparison, and the chips ...
Biology Products: